OOIR: Observatory of International Research

Papers

(The median citation count of Current Hematologic Malignancy Reports is 3. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-11-01 to 2025-11-01.)

Article	Citations
Monoclonal Gammopathy-Associated Neuropathy	119
Financial Toxicity in Patients with Hematologic Malignancies: a Review and Need for Interventions	30
Sporadic and Familial Acute Myeloid Leukemia with CEBPA Mutations	24
Telomere Biology Disorder: A Focus on Gastrointestinal and Hepatic Manifestations	20
Mutant Calreticulin in MPN: Mechanistic Insights and Therapeutic Implications	19
Management of Chronic Myeloid Leukemia in Children and Young Adults	18
Contemporary Updates in the Prevention and Treatment of Graft-Versus-Host Disease	17
Correction to: Treatment of Myelodysplastic Syndromes for Older Patients: Current State of Science, Challenges, and Opportunities	17
Value in Myeloma Care: Myth or Reality	16
Clonal Hematopoiesis in Myeloproliferative Neoplasms Confers a Predisposition to both Thrombosis and Cancer	15
Splicing Factor Mutations in Chronic Myelomonocytic Leukemia: Biological Consequences and Therapeutic Implications	15
Transplantation and Cellular Therapy for Older Adults—The MSK Approach	14
Targeting Apoptosis in ALL	14
Allogeneic Transplant for CMML	13
Prognostic and Predictive Models in Myelofibrosis	12
Multidisciplinary Approach to Older Adults with Hematologic Malignancies—a Paradigm Shift	12
Diagnosis and Management of Pulmonary Manifestations of Telomere Biology Disorders	12
Management of Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma in the Era of Targeted Therapies	11
New Molecular and Biological Markers in Cutaneous T Cell Lymphoma: Therapeutic Implications	11
How Do We Manage Chronic Lymphocytic Leukemia in India	11
Multiple Myeloma: Current Clinical Landscape and Compounding Costs	11
Advances in Risk Stratification and Treatment of Polycythemia Vera and Essential Thrombocythemia	10
Therapy Resistance and Disease Progression in CML: Mechanistic Links and Therapeutic Strategies	10
Progress and Challenges in Survivorship After Acute Myeloid Leukemia in Adults	8
Germline CHEK2 and ATM Variants in Myeloid and Other Hematopoietic Malignancies	8

CAR-T Cell Therapy: the Efficacy and Toxicity Balance	8
Novel Approaches to Managing Patients with Relapsed and Refractory Waldenström Macroglobulinemia	8
Developing Targeted Therapies for T Cell Acute Lymphoblastic Leukemia/Lymphoma	8
Family Planning and Pregnancy in Patients with Chronic Myeloid Leukemia	8
Updates in the Classification of T-cell Lymphomas and Lymphoproliferative Disorders	8
Adaptive and Maladaptive Clonal Hematopoiesis in Telomere Biology Disorders	8
Prevalence and Determinants of Return to Work as a Patient-Centered Outcome in Survivors of Hematopoietic Cell Transplantation	7
Role of Population Based Studies in Advancing our Knowledge of Myelodysplastic Syndromes	7
Myeloproliferative Neoplasms with Monocytosis	7
Management of Toxicities Associated with BCMA, GPRC5D, and FcRH5-Targeting Bispecific Antibodies in Multiple Myeloma	6
Impact of Epigenetic Mutations in Chronic Myelomonocytic Leukemia	6
Pediatric Germline Predisposition to Myeloid Neoplasms	6
An Update on the Management of Advanced Phase Chronic Myeloid Leukemia	6
Maintenance Therapy Post-Stem Cell Transplantation for Patients with T-Cell Lymphomas	6
Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)	5
Approach to the patient with eosinophilia in the era of tyrosine kinase inhibitors and biologicals	5
Role of Germline Predisposition to Therapy-Related Myeloid Neoplasms	5
Germline and Somatic Defects in DDX41 and its Impact on Myeloid Neoplasms	5
Highlights from MPN Asia 2025: Advances in Molecular Pathogenesis and Therapeutic Strategies in Myeloproliferative Neoplasms	5
Emerging Significance and Implications of a Durable Complete Molecular Remission in the Treatment of Polycythemia Vera	5
JAK Inhibitors for Myelofibrosis: Strengths and Limitations	5
Novel Therapies in Myelofibrosis: Beyond JAK Inhibitors	4
Measurable Residual Disease Monitoring in Lymphoma	4
Germline Abnormalities in DNA Methylation and Histone Modification and Associated Cancer Risk	4
Defining Higher-Risk Chronic Myeloid Leukemia: Risk Scores, Genomic Landscape, and Prognostication	4
Managing Survivorship after Hematopoietic Cell Transplantation	4
Real-world Management of CML: Outcomes and Treatment Patterns	4
NK Cell Therapeutics for Hematologic Malignancies: from Potential to Fruition	3
A Journey Through JAK Inhibitors for the Treatment of Myeloproliferative Diseases	3
Use of Telemedicine in Care of Hematologic Malignancy Patients: Challenges and Opportunities	3
Targeted Therapy for MPNs: Going Beyond JAK Inhibitors	3
Treatment of Myelodysplastic Syndromes for Older Patients: Current State of Science, Challenges, and Opportunities	3
Clonal Hematopoiesis and Myeloid Neoplasms in the Context of Telomere Biology Disorders	3
Use of Patient-Reported Outcome Measures in Clinical Studies of Chronic Myeloid Leukemia: A Scoping Literature Review	3
Management of CNS Disease in Pediatric Acute Lymphoblastic Leukemia	3
The Role of Inflammation in CMML Pathobiology and Progression	3
Use of Patient-Centered Technology and Digital Interventions in Pediatric and Adult Patients with Hematologic Malignancies	3